Finland's Oriola Q3 net sales rise 5.1%

Overview

• Finland pharmaceutical distributor's Q3 net sales rose 5.1% year-over-year

• Q3 earnings per share were unchanged from a year earlier

• Adjusted EBITDA flat yr/yr on one-off inventory provision

Outlook

• Oriola expects 2026 adjusted EBITDA to increase from 2025's €35.1 mln

• Company expects pharmaceutical distribution market growth in 2026, led by high-value products

• Company sees ongoing geopolitical uncertainty and continued availability issues for some pharmaceuticals

Result Drivers

• SPECIALITY FLOWS AND WHOLESALE - Co said Q3 net sales growth was driven by high volumes in speciality flows, wholesale sales, and strong sales in special-licensed medicines

• FUEL COST PASS-THROUGH - Oriola said it mitigated higher fuel prices by passing costs through to customers

• INVENTORY PROVISION - One-off inventory provision of €0.7 mln offset profitability gains

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Oriola Oyj is €0.85, about 13% above its October 28 closing price of €0.75

• The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 10 three months ago

Reuters Recommended Reads

• Oct 28 - Finland's Orion Q3 sales rise 28%; upgrades 2026 outlook

• Oct 27 - Novartis slightly misses Q3 net sales estimates, but tops core EPS view

• Oct 27 - Pharming Group Q3 revenue rises on US demand; tightens guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)